erbB-2 Receptor – Talk Bio

FDA Approves Roche’s PATHWAY HER2 Test for HER2-Ultralow Metastatic Breast Cancer

3 months ago talkbio0Tagged Approved, Biochemical Pathway, Carcinoma breast stage IV, Diagnosis, Enhertu, erbB-2 Receptor, HER2-ultralow, Pet Animal, Precision Medicine, Roche (company), United States Food and Drug Administration

Roche, PATHWAY HER2 (4B5) test, FDA approval, HER2-ultralow, metastatic breast cancer, companion diagnostic, Enhertu, personalized medicine

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

4 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision

11 months ago talkbio0Tagged Biliary Tract Cancer, Decision, erbB-2 Receptor, Jazz, Priority Review, United States Food and Drug Administration, Zanidatamab

Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review